Apologies, I found the full year 2023 stuff which has not been posted here in HC, along with a lot of other stuff missing, which is strange:
In 2022 EYE had revenues (sales/gross income) of $13.378 mil and a net loss of $7.817 - expenses of $21.195 mil.
In 2023 EYE had revenue of $17 mil and a loss of $17 mil, so expenses of $34 mil, of which there was $6.044 mil recorded as a one off impairment, obviously with normalised expenses of $28 mil.
In 2024 income has been $23.5 mil, so it remains to be seen how much expenses have risen. They are expected to have risen substantially and there will be a significant loss.
*The impairment item was due to the inability of the AlphaRET segment to generate independent cashflows, requiring a cash investment of $6.044 mil, more than the company had available. Not quite a one off non cash item as characterised by TheAnalyst007
- Forums
- ASX - By Stock
- CMS Proposes Major Increase in Reimbursement for Canaloplasty
Apologies, I found the full year 2023 stuff which has not been...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EYE (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.0¢ |
Change
-0.005(2.56%) |
Mkt cap ! $43.52M |
Open | High | Low | Value | Volume |
20.0¢ | 20.0¢ | 19.0¢ | $65.41K | 338.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 81174 | 19.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.5¢ | 60000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 81174 | 0.190 |
1 | 2710 | 0.185 |
4 | 177246 | 0.180 |
4 | 92714 | 0.175 |
3 | 8900 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.195 | 60000 | 1 |
0.200 | 69613 | 2 |
0.205 | 44282 | 2 |
0.210 | 223212 | 2 |
0.215 | 304291 | 5 |
Last trade - 16.10pm 16/09/2024 (20 minute delay) ? |
Featured News
EYE (ASX) Chart |